Upstream Bio, Inc. business relationships
Companies named in Upstream Bio, Inc.’s 10-K filed 2026-03-26, and public companies whose annual reports name Upstream Bio, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 6% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Upstream Bio, Inc.’s annual report 3
“Under the Regeneron Letter Agreement, we assumed from Astellas an obligation to make mid-single-digit percentage royalty payments to Regeneron upon the commercialization of products developed from materials originally licensed to Astellas.” SEC filing
“The Regeneron Letter Agreement relates to a prior Non-Exclusive License and Material Transfer Agreement (the "Terminated Regeneron License Agreement") that Regeneron and Astellas entered into in March 2007, as amended in July 2010 and subsequently terminated in June 2018, subject to certain survivin...” SEC filing
“License Agreement, by and between the Company and Lonza Sales AG, dated October 21, 2021, as amended (incorporated by reference to Exhibit 10.15 to the Company's Registration Statement on Form S-1 filed on September 18, 2024).” SEC filing
Links are read automatically from public company filings, so every link carries the sentence it came from.
Not investment advice. Scores, rankings and connections are automated estimates from public sources, provided as is. Connections are read automatically from public company filings and may be incomplete or wrong. To correct or remove a company page or a connection, email [email protected]. Company names and logos belong to their owners. Showing them does not mean the company endorses Engagemii or that Engagemii endorses it. Terms